BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 27, 2026
View BioWorld MedTech
Home
» Use of outside counsel for quality systems investigations carries limited privilege
To read the full story,
subscribe
or
sign in
.
2022 FDLI Enforcement Conference
Use of outside counsel for quality systems investigations carries limited privilege
Dec. 9, 2022
By
Mark McCarty
Medical device manufacturers that hire outside counsel to conduct investigations of a facility’s quality system can expect an outsider’s view and might have the benefit of more candor on the part of quality staff than would otherwise be available.
Medical technology